News

#CMSC16 – Novel Model of Home Care for Patients with Progressive MS Proven Beneficial, Increased Patients’ Satisfaction

A new model of care implemented to address the needs of patients with progressive multiple sclerosis (MS) and their caregivers has provenĀ beneficial by reducing hospital stays, avoiding major care expenses, and improving patients’ satisfaction. The model has been tested in MS patients with high disability scores, and preliminary results of…

#CMSC16 – Interview with Bayer’s VP and General Manager on Betaconnect/Betaseron and Customized Therapy

Global pharmaĀ Bayer HealthcareĀ aims toĀ improve human health by diagnosing, preventing, and treating a variety of diseases. The company currently provides products for general medicine, hematology, neurology, oncology, and women’s healthcare. In 1993, Bayer’s BetaseronĀ (interferon beta-1b) became the first disease-modifying drugĀ to be approved by the U.S. Food and Drug Administration (FDA)Ā for…

#CMSC16 – Home Evaluation Prototype to Improve At-home Rehabilitation After Hospitalization

Researchers at the Shepherd Center in Atlanta areĀ developing a prototype that addresses physical and cognitive parameters, daily routines, and homes of patients to better implement rehabilitation within the home environment. The study wasĀ presented in “Functional Home Evaluation: Missing Pieces in Treatment and Transition Processes” during the Consortium…

#CMSC16 – Study of PPMS Patient Characteristics Highlights Need for More Information

PeopleĀ with primary progressive multiple sclerosis (PPMS)Ā are usually older and more disabled than thoseĀ withĀ relapsing-remitting MS, researchers atĀ Washington UniversityĀ reported. The team is studying demographic and clinical characteristics of PPMS patients enrolled in theĀ NARCOMSĀ registry, to better understand their unmet needs and possibly improve research into potential treatments. The study, ā€œ…

#CMSC16 – Visual Assessment May Provide Information on Cognitive Function in MS Patients

Researchers at Johns Hopkins University in Baltimore found that visual function in multiple sclerosis (MS) patients correlates with cognitive function ands suggests that disease severity and outcomes of neuroprotective therapies in MS patients may be assessed through visual function measurements. The findings were recently presentedĀ in the oral presentation “…

#CMSC16 – Treadmill Walking Improves Cognitive Processing in MS Patients

Treadmill walking exercise training is beneficial for multiple sclerosis (MS) patients, increasing not only their cardiorespiratory fitness, but also their cognitive processing speed, according to the study “Systematically Developed Pilot Randomized Controlled Trial of Exercise and Cognition in Persons with Multiple Sclerosis,” recently presented at theĀ Consortium of Multiple…

#CMSC16 – Robot-assisted Rehabilitation May Improve MS Patient Locomotor Function

Robot-assisted training may be anĀ effective therapy to improve motor function in the lower limbs of patients with multiple sclerosis (MS), and help in rehabilitation, according to the study “Robot-Guided Rehabilitation Improves Sensorimotor Functions in Lower-Limb Impairments of Individuals with Multiple Sclerosis,” presented at theĀ Consortium of Multiple Sclerosis Centers…

#CMSC16 – Medical Affairs VP at EMD Serono Discusses MS Drug Rebif, MS LifeLines Support in Exclusive Interview

EMD Serono,Ā the U.S. and Canadian subsidiary and biopharmaceutical business of Merck KGaA,Ā focuses exclusively on specialty care. With expertise inĀ fertility, endocrinology, oncology and neurology, the company is featuring several innovative products with therapeutic potential in the oncology, immuno-oncology, and immunology fields. Rebif (interferon beta-1a), EMD Serono’s therapyĀ for patients withĀ relapsing…

#CMSC16 – Lifestyle Factors and Unconventional Medicine in MS Care

A symposium focused on lifestyle factors and unconventional medicine as part of the clinical care provided to patients with multiple sclerosis (MS) took placeĀ today at theĀ 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC). The symposium, “Expanding the MS Toolkit: Integrating Lifestyle Factors and Unconventional Medicine…

#CMSC16 – MS Expert Fred Lublin Discusses Relevance of MS Relapses

Dr. Fred Lublin,Ā a renowned multiple sclerosis (MS) expert atĀ Mount Sinai Medical Center, helped launch theĀ Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting,Ā June 1 – 4, in National Harbor, Md. with the John F. Kurtzke Memorial Lecture he titledĀ ā€œDo Relapses Really Matter?ā€ ā€œHow relapses influence disease worsening,…

#CMSC16 – Patricia Coyle, an MS Expert, Talks About Vitamin D, Fatigue and Other Key Issues

TheĀ Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual MeetingĀ began today, June 1. Multiple Sclerosis News TodayĀ isĀ providing extensive on-site coverage of the meeting, reporting on presentations, and conducting exclusive interviews with top researchers in the field of multiple sclerosis (MS) and with biopharmaceutical representatives on the latest advances in MS therapies.

MS Research Australia Supporting Effort to Harness Anti-inflammatory Potential of Parasitic Worms

Researchers at theĀ University of Technology Sydney (UTS) ithree instituteĀ are takingĀ a novel approachĀ in an attempt toĀ halt disease progression in multiple sclerosis (MS). The scientists are planning to explore the anti-inflammatory potential of a controlled infection by parasitic worms as a way of preventing the harmful over-inflammation observed in MS and…

MedDay Presents Phase 3 Extension Data on Potential Drug to Treat Progressive MS

Data from an extension phase of aĀ Phase 3 clinical trial, given in an oral presentation by MedDay, reportedĀ that the biotinĀ Ā MD1003 showedĀ effectiveness over time as a possibleĀ treatment of non-active, progressive multiple sclerosis (MS). The dataĀ were presented atĀ the recentĀ 2nd Congress of the European Academy of Neurology (EAN) in DenmarkĀ byĀ ProfessorĀ Ayman Tourbah,…

Report Highlights Series of Changes Needed from Canadian Employers and Government to Improve MS Patients’ Lives

A new report by the Conference Board of Canadaā€™sĀ Canadian Alliance for Sustainable Health Care (CASHC)Ā notesĀ that employers and the Canadian government are not giving enough support towardsĀ increasing workforce participation among patients with multiple sclerosis (MS), despite the clear benefits such support would mean to not only the well-being of individuals…

R-Pharm Group To Launch Glatirat, an Analogue of Copaxone for MS Treatment

The Russian Ministry of HealthĀ recently granted Marketing Authorization (Š›ŠŸ-003567) to R-Pharm JSC for the development of Ā ā€œGlatiratā€ (Glatiramer acetate), a drug intended for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS) and clinically isolated syndrome. According to a press release, the registration of ā€œGlatiratā€ was based…